[New therapeutic strategy for autoimmune diseases. 2) Abnormality in expression of cell surface molecules in systemic erythematodes and its therapeutic application].
Takasaki
Y
Y
Abe
K
K
Tokano
Y
Y
Hashimoto
H
H
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D018122:B7-1 Antigen / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy; D018799:Intercellular Adhesion Molecule-1 / Q000097:blood*; D008180:Lupus Erythematosus, Systemic / Q000276:immunology* / Q000628:therapy; D016169:Lymphocyte Function-Associated Antigen-1 / Q000097:blood*; D008214:Lymphocytes / Q000276:immunology*; D051379:Mice; D016513:Mice, SCID
D000911:Antibodies, Monoclonal; D018122:B7-1 Antigen; D016169:Lymphocyte Function-Associated Antigen-1; D018799:Intercellular Adhesion Molecule-1